CN Mobile Logo

Search form


Higher Radiation Doses Reduce Recurrence Rates in Patients With Aggressive Prostate Tumors

Higher Radiation Doses Reduce Recurrence Rates in Patients With Aggressive Prostate Tumors

A multi-institutional study demonstrated that prostate cancer patients with aggressive tumors benefited from higher-than-standard doses of radiation. In the trial, 79% of 102 patients receiving radiation therapy for cancer confined to the prostate were cancer free at 5 years. In contrast, more than half of patients who undergo radical prostatectomy experience a recurrence at 5 years. Dr. John B. Fiveash, formerly of the University of Michigan and now at the University of Alabama Birmingham Medical Center led the study, which was conducted at the University of Michigan in Ann Arbor, Fox Chase Cancer Center in Philadelphia, and the University of California in San Francisco.

Three-Dimensional Conformal Radiotherapy

All evaluable patients had Gleason scores between 8 and 10, said Dr. Fiveash. Under the microscope, these tumors appear more aggressive, and account for a higher percentage of prostate cancer deaths.

“Patients in the study received a range of radiation doses from conventional (< 70 Gy) to 80 Gy,” said Dr. Fiveash. “The higher the dose, the better the patient did.” Conventional doses for prostate cancer are between 66 Gy and 70 Gy, but higher doses of radiation can be delivered using three-dimensional conformal radiotherapy. The technique was used for all patients in the study, which was reported in a recent issue of the International Journal of Radiation Oncology, Biology and Physics.

Three-dimensional conformal radiotherapy requires technical expertise and appropriate treatment planning, Dr. Fiveash noted. “If we are to make headway in treating this disease, we must invest in training and equipment so this technique is available in community hospitals as well as major medical centers,” he added.

Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.